In light of the bidirectional relationship between NAFLD and sarcopenia and the significantly higher cardiovascular risk in obese sarcopenic patients compared to non-sarcopenic ones [143], GLP-1 RAs could guarantee additional direct benefits independent from weight loss and glycaemic control. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.